Xin Yan1, Yujuan Gao1, Jingzhi Tong1, Mi Tian1, Jinghong Dai1, Yi Zhuang1. 1. Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Abstract
BACKGROUND: Numerous studies showed that insulin resistance (IR) was associated with cancer risk. However, few studies investigated the relationship between IR and non-small cell lung cancer (NSCLC). The aim of this study is to explore the association of triglyceride glucose (TyG) index, a simple surrogate marker of IR, with NSCLC risk. METHODS: 791 histologically confirmed NSCLC cases and 787 controls were enrolled in the present study. Fasting blood glucose and triglyceride were measured. The TyG index was calculated as ln [fasting triglycerides (mg/dl) ×fasting glucose (mg/dl)/2]. Logistic regression analysis was performed to estimate the relationship between NSCLC risk and the TyG index. RESULTS: The TyG index was significantly higher in patients with NSCLC than that in controls (8.42 ± 0.55 vs 8.00 ± 0.45, P < 0.01). Logistic regression analysis showed that the TyG index (OR = 3.651, 95%CI 2.461-5.417, P < 0.001) was independently associated with NSCLC risk after adjusting for conventional risk factors. In addition, a continuous rise in the incidence of NSCLC was observed along the tertiles of the TyG index (29.4 vs 53.8 vs 67.2%, P < 0.001). However, there were no differences of the TyG index in different pathological or TNM stages. In receiver operating characteristic (ROC) curve analysis, the optimal cut-off level for the TyG index to predict incident NSCLC was 8.18, and the area under the ROC curve (AUROC) was 0.713(95% CI 0.688-0.738). CONCLUSIONS: The TyG index is significantly correlated with NSCLC risk, and it may be suitable as a predictor for NSCLC.
BACKGROUND: Numerous studies showed that insulin resistance (IR) was associated with cancer risk. However, few studies investigated the relationship between IR and non-small cell lung cancer (NSCLC). The aim of this study is to explore the association of triglyceride glucose (TyG) index, a simple surrogate marker of IR, with NSCLC risk. METHODS: 791 histologically confirmed NSCLC cases and 787 controls were enrolled in the present study. Fasting blood glucose and triglyceride were measured. The TyG index was calculated as ln [fasting triglycerides (mg/dl) ×fasting glucose (mg/dl)/2]. Logistic regression analysis was performed to estimate the relationship between NSCLC risk and the TyG index. RESULTS: The TyG index was significantly higher in patients with NSCLC than that in controls (8.42 ± 0.55 vs 8.00 ± 0.45, P < 0.01). Logistic regression analysis showed that the TyG index (OR = 3.651, 95%CI 2.461-5.417, P < 0.001) was independently associated with NSCLC risk after adjusting for conventional risk factors. In addition, a continuous rise in the incidence of NSCLC was observed along the tertiles of the TyG index (29.4 vs 53.8 vs 67.2%, P < 0.001). However, there were no differences of the TyG index in different pathological or TNM stages. In receiver operating characteristic (ROC) curve analysis, the optimal cut-off level for the TyG index to predict incident NSCLC was 8.18, and the area under the ROC curve (AUROC) was 0.713(95% CI 0.688-0.738). CONCLUSIONS: The TyG index is significantly correlated with NSCLC risk, and it may be suitable as a predictor for NSCLC.
Authors: Gabriella Andreotti; Neal D Freedman; Debra T Silverman; Catherine C Lerro; Stella Koutros; Patricia Hartge; Michael C Alavanja; Dale P Sandler; Laura Beane Freeman Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-12-29 Impact factor: 4.254
Authors: Demetrius Albanes; Stephanie J Weinstein; Margaret E Wright; Satu Männistö; Paul J Limburg; Kirk Snyder; Jarmo Virtamo Journal: J Natl Cancer Inst Date: 2009-08-21 Impact factor: 13.506
Authors: Milana Bergamino; Antonio J Rullan; Maria Saigí; Inmaculada Peiró; Eduard Montanya; Ramón Palmero; José Carlos Ruffinelli; Arturo Navarro; María Dolores Arnaiz; Isabel Brao; Samantha Aso; Susana Padrones; Felipe Cardenal; Ernest Nadal Journal: BMC Cancer Date: 2019-02-21 Impact factor: 4.430